WO2005007239B1 - Uso de la dapsona como neuroprotector en el infarto cerebral - Google Patents
Uso de la dapsona como neuroprotector en el infarto cerebralInfo
- Publication number
- WO2005007239B1 WO2005007239B1 PCT/MX2004/000018 MX2004000018W WO2005007239B1 WO 2005007239 B1 WO2005007239 B1 WO 2005007239B1 MX 2004000018 W MX2004000018 W MX 2004000018W WO 2005007239 B1 WO2005007239 B1 WO 2005007239B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dapsone
- cerebral infarction
- neuroprotector
- infarction
- modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Mobile Radio Communication Systems (AREA)
Abstract
La presente invención, tiene por objeto demostrar el uso de la dapsona como el primer tratamiento eficaz contra las consecuencias incapacitantes asociadas con el infarto cerebral en estos pacientes. La dapsona fue evaluada como neuroprotector, en el modelo de infrato cerebral producido por la oclusión de la arteria cerebral media en el las ratas y en pacientes que sufrieron un infarto cerebral agudo por trombo-embolismo- En ambos estudios la dapsona demostró una reducción de entre 70 y 90% de las consecuencias adversas que se presentan como consecuencia del infarto.
Claims
REIVINDICACIONES MODIFICADAS
[Recibidas por la Oficina Internacional el 20 de agosto de 2004 (20.08.2004): reivindicaciones 1 a 5, reemplazadas por las reivindicaciones modificadas 1 a 4] Habiendo descrito el invento, se considera como una novedad el uso de la dapsona para el tratamiento del infarto cerebral agudo y por lo tentó se reclama como propiedad lo contenido en las siguientes cláusulas:
1) El uso de la dapsona para preparar un medicamento para el tratamiento del infarto cerebral. 2) El uso de la dapsona, de conformidad con la reivindicación 15 en donde el medicamento es de administración oral.
3) El uso de la dapsona, de conformidad con la reivindicación 2, en donde el medicamento de administración oral es una suspensión.
4) El uso de la dapsona, de conformidad con la reivindicación 3, en donde la suspensión contiene 200 g. de dapsona.
HOJA MODIFICADA (ARTICUL019)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04721040A EP1655055B1 (en) | 2003-07-22 | 2004-03-16 | Use of dapsone as a neuroprotector in cerebral infarction |
| EA200600272A EA012174B1 (ru) | 2003-07-22 | 2004-03-16 | Применение дапсона в качестве нейропротектора при остром церебральном инфаркте |
| US10/565,309 US8268893B2 (en) | 2003-07-22 | 2004-03-16 | Use of dapsone as a neuroprotector in cerebral infarction |
| CA2533181A CA2533181C (en) | 2003-07-22 | 2004-03-16 | Use of dapsone as neuroprotector in the brain stroke |
| DE602004006633T DE602004006633T2 (de) | 2003-07-22 | 2004-03-16 | Verwendung von dapson als neuroprotektor bei zerebralinfarkt |
| BRPI0412212-7A BRPI0412212A (pt) | 2003-07-22 | 2004-03-16 | uso da dapsona como neuroprotetor no infarto cerebral |
| JP2006521015A JP5452844B2 (ja) | 2003-07-22 | 2004-03-16 | 脳梗塞における神経プロテクターとしてのダプソンの使用方法。 |
| HK07104433.0A HK1098086A1 (en) | 2003-07-22 | 2007-04-25 | Use of dapsone as a neuroprotector in preparing medicament for brain stroke |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA/A/2003/006549 | 2003-07-22 | ||
| MXPA03006549A MXPA03006549A (es) | 2003-07-22 | 2003-07-22 | Uso de la dapsona como neuroprotector en el infarto cerebral. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005007239A1 WO2005007239A1 (es) | 2005-01-27 |
| WO2005007239B1 true WO2005007239B1 (es) | 2005-05-06 |
Family
ID=34075071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/MX2004/000018 WO2005007239A1 (es) | 2003-07-22 | 2004-03-16 | Uso de la dapsona como neuroprotector en el infarto cerebral |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8268893B2 (es) |
| EP (1) | EP1655055B1 (es) |
| JP (1) | JP5452844B2 (es) |
| CN (1) | CN100500246C (es) |
| AT (1) | ATE362783T1 (es) |
| BR (1) | BRPI0412212A (es) |
| CA (1) | CA2533181C (es) |
| DE (1) | DE602004006633T2 (es) |
| EA (1) | EA012174B1 (es) |
| EC (1) | ECSP066316A (es) |
| ES (1) | ES2287713T3 (es) |
| HK (1) | HK1098086A1 (es) |
| MX (1) | MXPA03006549A (es) |
| PT (1) | PT1655055E (es) |
| WO (1) | WO2005007239A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009004635A (es) * | 2009-04-29 | 2010-10-29 | Univ Autonoma Metropolitana | Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades. |
| KR101875705B1 (ko) * | 2011-12-07 | 2018-07-06 | 삼성전자주식회사 | 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN104177610A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
| CN104177611A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
| CN104069091A (zh) * | 2014-07-09 | 2014-10-01 | 崔德华 | 氨苯砜在保护血脑屏障完整性中的应用 |
| KR20160047318A (ko) * | 2014-10-22 | 2016-05-02 | 삼성전자주식회사 | 다프손을 포함하는, 개체의 부위에서 혈관신생을 자극시키기 위한 조성물 및 그의 용도 |
| KR20200107899A (ko) * | 2019-11-16 | 2020-09-16 | 이종훈 | 알츠하이머병 혹은 뇌졸중의 뉴로인플라마섬의 치료제로서 디디에스 혹은 그 유도체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532219A (en) * | 1991-04-23 | 1996-07-02 | The University Of British Columbia | Dapsone and promin for the treatment of dementia |
| JP2002520419A (ja) * | 1998-07-15 | 2002-07-09 | ヨマー、ハッサン | リン有機化合物およびその使用 |
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
-
2003
- 2003-07-22 MX MXPA03006549A patent/MXPA03006549A/es active IP Right Grant
-
2004
- 2004-03-16 ES ES04721040T patent/ES2287713T3/es not_active Expired - Lifetime
- 2004-03-16 PT PT04721040T patent/PT1655055E/pt unknown
- 2004-03-16 US US10/565,309 patent/US8268893B2/en not_active Expired - Fee Related
- 2004-03-16 EP EP04721040A patent/EP1655055B1/en not_active Expired - Lifetime
- 2004-03-16 AT AT04721040T patent/ATE362783T1/de not_active IP Right Cessation
- 2004-03-16 CA CA2533181A patent/CA2533181C/en not_active Expired - Fee Related
- 2004-03-16 WO PCT/MX2004/000018 patent/WO2005007239A1/es active IP Right Grant
- 2004-03-16 JP JP2006521015A patent/JP5452844B2/ja not_active Expired - Fee Related
- 2004-03-16 EA EA200600272A patent/EA012174B1/ru not_active IP Right Cessation
- 2004-03-16 DE DE602004006633T patent/DE602004006633T2/de not_active Expired - Lifetime
- 2004-03-16 BR BRPI0412212-7A patent/BRPI0412212A/pt not_active IP Right Cessation
- 2004-03-16 CN CNB2004800264451A patent/CN100500246C/zh not_active Expired - Fee Related
-
2006
- 2006-01-25 EC EC2006006316A patent/ECSP066316A/es unknown
-
2007
- 2007-04-25 HK HK07104433.0A patent/HK1098086A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1098086A1 (en) | 2007-07-13 |
| CN100500246C (zh) | 2009-06-17 |
| EP1655055B1 (en) | 2007-05-23 |
| US20100063159A1 (en) | 2010-03-11 |
| CA2533181A1 (en) | 2005-01-27 |
| EA200600272A1 (ru) | 2006-10-27 |
| DE602004006633D1 (de) | 2007-07-05 |
| DE602004006633T2 (de) | 2008-01-31 |
| US8268893B2 (en) | 2012-09-18 |
| EP1655055A1 (en) | 2006-05-10 |
| EA012174B1 (ru) | 2009-08-28 |
| ECSP066316A (es) | 2006-10-25 |
| ES2287713T3 (es) | 2007-12-16 |
| PT1655055E (pt) | 2007-08-31 |
| JP5452844B2 (ja) | 2014-03-26 |
| CN1852749A (zh) | 2006-10-25 |
| BRPI0412212A (pt) | 2006-08-22 |
| ATE362783T1 (de) | 2007-06-15 |
| JP2006528175A (ja) | 2006-12-14 |
| CA2533181C (en) | 2012-08-07 |
| MXPA03006549A (es) | 2004-03-18 |
| WO2005007239A1 (es) | 2005-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY148108A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| WO2006017188A3 (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| WO2005023083A3 (en) | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) | |
| FI3628319T3 (fi) | Hepaattisen enkefalopatian hoito rifaksimiinilla | |
| WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
| HK1123213A1 (en) | Reduction of dizziness, a side effect associated with pirfenidone therapy | |
| WO2007087241A3 (en) | Treatment of ischemic disease using thrombopoietin | |
| WO2007019184A3 (en) | Oral suspension of prednisolone acetate | |
| WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| TW200635595A (en) | Medicaments for the treatment of prevention of fibrotic diseases | |
| WO2005007239B1 (es) | Uso de la dapsona como neuroprotector en el infarto cerebral | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| WO2007130509A3 (en) | Pyrroloquinoline quinones and use thereof | |
| WO2007149366B1 (en) | Prolonged improvement of renal function comprising infrequent administration of an aa1ra | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| HRP20080255A2 (en) | Use of cicletanine and other furopyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension | |
| EP1609473A8 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| CA2396209A1 (en) | The use of mirtazapine for the treatment of sleep disorders | |
| WO2005107871A3 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury | |
| SI1714647T1 (sl) | Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj | |
| MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
| WO2002022211A3 (en) | Reduction of the electrocardiographic ot interval | |
| WO2007144889A3 (en) | Treatment of neurofibromatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200480026445.1 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| B | Later publication of amended claims |
Effective date: 20040820 |
|
| ENP | Entry into the national phase |
Ref document number: 2533181 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006521015 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 06016589 Country of ref document: CO Ref document number: 200600272 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004721040 Country of ref document: EP Ref document number: 899/DELNP/2006 Country of ref document: IN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004721040 Country of ref document: EP |
|
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: PI0412212 Country of ref document: BR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10565309 Country of ref document: US |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2004721040 Country of ref document: EP |